Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

SIMPLE SUMMARY: Patients with “HER2-positive” early breast cancer are treated with antibodies to the HER2 protein along with chemotherapy, regardless of whether their cancer also has hormone receptors, or of its molecular features. Because patients with HER2-positive/hormone receptor-positive diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Harbeck, Nadia, von Schumann, Raquel, Kates, Ronald Ernest, Braun, Michael, Kuemmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Malter, Wolfram, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, Grischke, Eva-Maria, Biehl, Claudia, Liedtke, Cornelia, De Haas, Sanne Lysbet, Deurloo, Regula, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Gluz, Oleg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508505/
https://www.ncbi.nlm.nih.gov/pubmed/34638369
http://dx.doi.org/10.3390/cancers13194884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508505/
https://www.ncbi.nlm.nih.gov/pubmed/34638369
http://dx.doi.org/10.3390/cancers13194884

Ejemplares similares